Disease Markers

Research Article

Associations of Genetic Polymorphisms of mTOR rs2295080 T/G and rs1883965 G/A with Susceptibility of Urinary System Cancers

Table 2

Stratified analysis of mTOR rs2295080 T/G and rs1883965 G/A polymorphisms on cancer susceptibility.


Variables		Case/control	OR (95% CI)			OR (95% CI)			OR (95% CI)			OR (95% CI)			OR (95% CI)
Variables		Case/control	M-allele vs. W-allele			MW vs. WW			MM vs. WW			MM+MW vs. WW			MM vs. MW+WW

rs2295080 T/G
Total	18	10447/11979	0.89 (0.80-0.98)	<0.001	0.023	0.88 (0.81-0.96)	0.004	0.004	0.84(0.65-1.07)	<0.001	0.162	0.87 (0.78-0.96)	<0.001	0.008	0.88 (0.70-1.11)	<0.001	0.288
Cancer type
Urinary	6	3738/4340	0.76 (0.62-0.94)	<0.001	0.010	0.77 (0.70-0.85)	0.522	<0.001	0.71 (0.44-1.17)	<0.001	0.178	0.74 (0.62-0.88)	0.004	0.001	0.82 (0.53-1.27)	<0.001	0.367
Blood	3	597/1146	1.24 (1.05-1.47)	0.480	0.013	1.06 (0.85-1.33)	0.691	0.578	2.12 (1.36-3.30)	0.263	0.001	1.17 (0.95-1.44)	0.722	0.142	2.08 (1.34-3.22)	0.225	0.001
Digestive	6	4462/4930	0.95 (0.83-1.08)	0.003	0.443	0.98 (0.85-1.13)	0.026	0.773	0.84 (0.71-1.01)	0.108	0.058	0.96 (0.82-1.12)	0.006	0.598	0.85 (0.72-1.01)	0.241	0.067
Breast	2	1090/1063	0.79 (0.68-0.91)	0.364	0.001	0.86 (0.72-1.03)	0.475	0.093	0.42 (0.27-0.66)	0.810	<0.001	0.80 (0.68-0.95)	0.380	0.012	0.45 (0.29-0.71)	0.909	<0.001
Others	1	560/500	0.79 (0.64-0.97)	-	0.027	0.78 (0.60-1.01)	-	0.060	0.67 (0.38-1.17)	-	0.158	0.76 (0.59-0.98)	-	0.033	0.73 (0.42-1.27)	-	0.261
Ethnicity
East Asian	17	10212/11725	0.92 (0.85-1.00)	<0.001	0.044	0.89 (0.82-0.97)	0.012	0.006	0.90 (0.72-1.11)	<0.001	0.315	0.89 (0.81-0.98)	0.001	0.013	0.93 (0.76-1.14)	<0.001	0.492
West Asian	1	235/254	0.38 (0.29-0.50)	-	<0.001	0.47 (0.27-0.82)	-	0.008	0.21 (0.12-0.36)	-	<0.001	0.30 (0.18-0.49)	-	<0.001	0.35 (0.24-0.50)	-	<0.001
Source
HB	12	6722/8310	0.94 (0.85-1.03)	<0.001	0.194	0.89 (0.81-0.98)	0.041	0.022	0.97 (0.74-1.27)	<0.001	0.803	0.90 (0.81-1.00)	0.006	0.056	1.00 (0.78-1.30)	<0.001	0.976
PB	6	3725/3669	0.78 (0.60-1.00)	<0.001	0.048	0.84 (0.69-1.02)	0.007	0.077	0.61 (0.37-1.02)	<0.001	0.061	0.77 (0.60-0.99)	<0.001	0.043	0.68 (0.45-1.02)	0.001	0.065
Method
TaqMan	14	9472/10550	0.90 (0.83-0.98)	<0.001	0.011	0.88 (0.81-0.97)	0.005	0.008	0.84 (0.70-1.01)	0.011	0.066	0.88 (0.80-0.97)	0.001	0.008	0.88 (0.74-1.04)	0.036	0.134
PCR-RFLP	3	415/846	0.89 (0.34-2.30)	<0.001	0.807	0.77 (0.44-1.34)	0.047	0.360	1.25 (0.16-9.53)	<0.001	0.829	0.75 (0.29-1.96)	<0.001	0.555	1.47 (0.26-8.18)	<0.001	0.659
Sequenom	1	560/583	0.84 (0.69-1.03)	-	0.089	0.91 (0.72-1.17)	-	0.467	0.45 (0.23-0.91)	-	0.027	0.86 (0.68-1.09)	-	0.225	0.47 (0.23-0.94)	-	0.033
rs1883965 G/A
Total	4	4300/4420	1.12 (1.00-1.24)	0.203	0.045	1.15 (1.02-1.29)	0.484	0.019	0.91 (0.54-1.54)	0.114	0.733	1.14 (1.02-1.27)	0.328	0.026	0.89 (0.53-1.51)	0.120	0.673
Cancer type
Urinary	1	1004/1051	1.06 (0.85-1.32)	-	0.621	1.05 (0.82-1.34)	-	0.700	1.21 (0.44-3.34)	-	0.718	1.06 (0.83-1.34)	-	0.655	1.20 (0.43-3.32)	-	0.728
Digestive	3	3296/3369	1.13 (1.00-1.28)	0.115	0.044	1.18 (1.03-1.34)	0.415	0.014	0.82 (0.44-1.53)	0.056	0.538	1.16 (1.02-1.32)	0.228	0.022	0.80 (0.43-1.49)	0.061	0.483
Source
HB	1	1048/1052	0.94 (0.75-1.17)	-	0.563	1.03 (0.81-1.31)	-	0.792	0.20 (0.04-0.92)	-	0.038	0.98 (0.78-1.24)	-	0.889	0.20 (0.04-0.91)	-	0.038
PB	3	3252/3368	1.18 (1.04-1.33)	0.484	0.009	1.19 (1.04-1.36)	0.489	0.011	1.28 (0.71-2.32)	0.626	0.416	1.19 (1.05-1.36)	0.479	0.009	1.25 (0.69-2.26)	0.627	0.467

HB: hospital based; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; PB: population based. ^aNumber of case-control studies. : value of heterogeneity test.